Neurocrine Biosciences Rolls Out Ingrezza Sprinkle Capsules to Treat Tardive Dyskinesia, Chorea With Huntington's Disease
Neurocrine Biosciences Rolls Out Ingrezza Sprinkle Capsules to Treat Tardive Dyskinesia, Chorea With Huntington's Disease
神经分泌生物科学推出Ingrezza Sprinkle胶囊用于治疗帕金森异动症、亨廷顿舞蹈症的舞蹈病
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册